colon specific drug delivery system: basics and approaches
TRANSCRIPT
COLON DRUG DELIVERY & APPROACHES
SWAPNIL N. JAIN(Assistant Professor, JES’s COP, Nandurbar)
1
Contents
Introduction Rational for the development of CDDS Drugs suitable for colon targeting Approaches for The colon targeting Evaluation parameters Conclusion References
2
3
Fig. Anatomy of GI Tract:
4
The role of digestive system is to break down complex molecules, derived from ingested food, into simple ones for absorption into the blood or the lymph.
This process occurs in five main phases, within defined regions of the gastrointestinal system-
• ingestion (mouth);• fragmentation (mouth and stomach);• digestion (stomach and small intestine);• absorption (small and large intestine);• elimination of waste products (large intestine).
Anatomy of colonIt is the lowermost part of gastrointestinaltract.
It is divided into four parts
Ascending colon Transverse colon Descending colon Sigmoid colon
The human large intestine is about 1.5m (5ft) in length.
Introduction
Fig 1. Anatomy of colon
5
6
Fig. Structure of colon wall
7
Location pH
Oral cavity 6.2-7.4
Oesophagus 5.0-6.0
Stomach 1.5-2.0 (Fasted condition)
3.0-5.0 (Fed Condition)
Small
intestine
5.0-6.5 (Jejunum)
6.0-7.5 (Ileum)
Large
intestine
6.4 (Ascending colon)
6.6-6.8 (Transverse colon)
6.8-7.6 (Descending colon)
Table pH values in the GI tract
8
Table: Transit time of various parts of GIT
9
Functions of colon
1)Creation of a suitable environment for the growth of colonic microorganisms.
2) Storage reservoir of fecal contents.
3) Expulsion of the contents of the colon at a suitable time and
4) Absorption of water and Na+ from the lumen, concentrating the fecal content, and secretion of K+ and HCO3
-.
10
Objectives
(a) To reduce dosing frequency.
(b) To delay delivery to the colon to achieve high local concentrations in the treatment of diseases of the distal gut.
(c) To delay delivery to a time appropriate to treat acute phases of disease (chronotherapy).
(d) To deliver to a region that is metabolically less hostile, e.g., to facilitate absorption of acid and enzymatically labile materials, especially peptides.
11
Factors affecting drug absorption from the colon:
1)Physical characteristics of drug (pKa, degree of ionization, etc.)2)Colonic residence time as dictated by gastrointestinal tract motility3)Degradation by bacterial enzymes and byproducts4)Selective and non-selective binding to mucus5)Use of chemical absorption enhancers, enzyme inhibitors, or bioadhesives
Rational for the development of colon targeted drug delivery systems
Drugs are available directly at the target site Less enzymatic activity Lesser amount of dose is required Bypass initial first pass metabolism Local and systemic treatment Proteins and peptides delivery Reduced gastric irritation (e.g. NSAIDS)
Limitations Establishment of an appropriate dissolution testing system Bioavailability of drug may be low Rate limiting step for poor soluble drugs
12
Drugs suitable for colon targeting
1. In the treatment of Inflammatory Bowel Disease (IBD) e.g., Sulphasalazine, Osalazine, Mesalazine
2. In the treatment of colonic cancer e.g., 5- fluorouracil, Doxorubicin, Methotrexate
3. Proteins and peptides drug delivery e.g., Calcitonin, Insulin, Erythropoietin
4. To treat infectious diseases like Ameobiasis e.g., Metronidazole, Albendazole
5. To treat Rheumatoid arthritis, Nocturnal asthma, Angina, Crohn’s disease, Ulcerative colitis, etc.
13
14
Strategies
1.Variable pH conditions throughout the GIT
2.Colonic microflora produce a variety of enzymes that are not present in the stomach or the small intestine
3.The relatively constant transit time in the small intestine of approximately 3–4 h
4.Another strategy relies on the strong peristaltic waves in the colon that lead to a temporarily increased luminal pressure.
Approaches For The Colon targeting
1.Primary approaches for colon targeting
I. pH sensitive polymer coatingII. Time controlled systemIII. Microbially triggered drug delivery
Polysaccharide based approach Prodrug approach
15
2. Novel approaches for colon targeting
I. Pressure controlled drug delivery system II. Osmotic controlled drug delivery to colonIII. Pulsincap system IV. Port system
16
l. pH sensitive polymer coating
Region pHAscending colon 6.4Transverse colon 6.6Descending colon 7.0
at colon pH
pH sensitive polymer
Drug core
Drug release
Important parameters - Selection of the appropriate polymers- Solubility at different pH environments
Primary approaches for colon targeting
17Fig 2. Drug release
Table. Polymers18
ll. Time controlled system
In these systems the release of the drug is decided by the transit time.
This system is useful for synchronous delivery of a drug either at preselected time or at a preselected site.
Fig3. Time controlled system
The formulation is comprised of 3 parts:-
1) a central core containing drug and swelling excipients. 2) an inner semi-permeable polymer membrane.
3) an outer enteric-coating which dissolves at or above pH 5.5
19
lll. Microbially triggered drug delivery
The colonic bacteria are predominately anaerobic in nature and secrete enzymes that are capable of metabolizing substrates that escape the digestion in the upper GI tract.
On reaching the colon, their is degradation of the polymer backbone by enzyme resulting in drug release.
Table: Enzymes in colon20
The hydrogels contain acidic co-monomers and enzymatically degradable azo-aromatic cross-links.
In the acidic pH of stomach, the gels have a low degree of swelling.
In colon, the gels reach a degree of swelling making the cross-links accessible to enzymes.
Azo hydrogels
21
Polysaccharide based approach
The polysaccharides are assessed to remain intact in physiological environment of stomach and small intestine.
As they reach colon they are acted upon bacterial polysaccharidases and results in degradation of the matrices.
e.g., Amylose, Pectin, Chitosan, Dextran, Guar gum, etc.
These are broken down by the colonic microflora to simple saccharides, so these fall into the category of “generally regarded as safe” (GRAS).
22
Prodrug approach
A prodrug is a pharmacologically inactive derivative of a parent molecule that requires some form of transformation in vivo to release the active drug at the target site.
Generally, a prodrug is successful as a colon drug carrier if it is hydrophilic and bulky to minimize absorption from the upper GIT, and is converted into more lipophilic in colon for absorption.
Limitation- It is not a very versatile approach as its formulation depends upon the functional group available on the drug moiety for chemical linkage.
23
l. Pressure controlled drug delivery system
As a result of peristalsis, higher pressures are encountered in the colon, and which forms the basis for this system.
Drug release occurs due to the disintegration of a water-insoluble polymer capsule because of pressure in the lumen of the colon.
The thickness of the polymer membrane is the critical factor for the disintegration of the formulation.
Novel approaches for colon targeting
24
ll. Osmotic controlled drug delivery to colonIt can be single osmotic unit or may incorporate as many as 5-6 units, each 4mm in diameter.
It can maintain a constant release rate for up to 24 h in the colon.
25Fig 4. OROS- CT
lll. Pulsincap system
It consists of non disintegrating half capsule body filled with drug content sealed at the opened end with the hydrogel plug, which is covered by water soluble cap.
Polymers used for hydrogel plug are HPMC, PVA etc.
Fig. Pulsincap system26
27Fig. Mechanism of drug release
lV. Port system
28Fig. Drug release
Evaluation1. In vitro
a) Dissolution testing b) Enzymatic degradation testing
2. In vivo
a) Drug delivery index
= Relative colonic tissue exposure to drug Relative amount of drug in blood
b) Animal studies c) γ-Scintigraphy – to investigate GI performance of a formulation
29
Marketed Formulations
30
Drug Trade name
Company name
Therapeutic use
Mesalamine Mesacol Sun Pharma Ulcerative colitisOsalazine Dipentum UCB Pharma Ulcerative colitis
Sulphasalazine Sazo Wallace Ulcerative colitis
Balsalazide Intazide Intas Ulcerative colitis
Diphenoxylate HCl+ Atropine sulphate
Lomotil RPG Life Mild ulcerative colitis
Mebeverine Colospa Solvay Irritable bowelsyndromeHydrocortisone acetate
Entofoam Cipla Ulcerative colitis
Conclusion
This system is of prime importance in the treatment of diseases and disorders related to colonic region.This drug delivery requires establishment of appropriate evaluation parameters.The discontinuity in physiological parameters along the GI tract governs few mechanisms to be incorporated to produce colon specific drug release.There is a need to identify appropriate approach, which will be safe, effective, less expensive with minimum fluctuation in drug release.
31
References1) Chourasia M. K., Jain S. K., (2003), Pharmaceutical Approaches to Colon Targeted Drug Delivery System, In: Journal of Pharmaceutical Sciences, 33-66.
2) Krishnaiah Y. S. R., Styanarayana S., (2000), Colon specific drug delivery systems. In: Jain N. K., ed. Advances in Controlled and Novel Drug Delivery. New Delhi, India: CBS Publishers and Distributors, 89-119.
3) Kothawade P. D., Gangurde H. H., Surawase R.K., Wagh M.A., Tamizharasi S.,Conventional and Novel Approaches for Colon Specific Drug Delivery: A Review. In : e- Journal of Science and Technology, 33-56.
4) Patel A., Bhatt N., (2011), Colon Targeted Drug Delivery System: A Review System, In: Journal of Pharmaceutical Sciences and Bioscientific Research, 37- 49.
5) Singh B.N., Kim K.H., In: Swarbrick J, Boylan JC., ed. (2002), Encyclopedia of Pharmaceutical Technology, New York, Marcel Dekker, Inc, 886-909.
32
6) Kumar K. V., Sivakumar T., Mani T., (2011), Colon Targeting Drug Delivery System: A review on recent approaches, In: International Journal of Biomedical Sciences, 11-19.
7) Mehta T. J., Patel A.D., (2011), Need of Colon Specific Drug Delivery System: Review on Primary and Novel Approaches, In: International Journal of Pharmaceutical Research and Development, 134-153.
8) Patel N., Patel J., (2008), Novel Pharmaceutical Approaches For Colon-Specific Drug Delivery: An Overview. In: Journal of Pharmacy Research, 2-10.
9) Prasanth V.V., Jayaprakash. R., Colon Specific Drug Delivery Systems: A Review on Various Pharmaceutical Approaches. In: Journal of Applied Pharmaceutical Science, 163-169.
33
THANK YOU
34